Trevi Therapeutics (TRVI) Cash from Investing Activities (2018 - 2026)

Trevi Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 270.49% year-over-year to $17.0 million in Q1 2026; TTM through Mar 2026 was -$67.2 million, a 187.29% decrease from a year earlier, with the FY2025 full-year figure at -$94.1 million, down 337.14% from the prior year.
• Cash from Investing Activities grew to $17.0 million in Q1 2026 per TRVI's latest filing, from -$30.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $19.6 million in Q2 2023 and bottomed at -$50.9 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is -$2.6 million (2025), against an average of -$6.2 million.
• Across the five-year window, Cash from Investing Activities jumped 470.76% in 2023 and tumbled 764.38% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$48.3 million in 2022, then surged by 126.59% to $12.8 million in 2023, then tumbled by 285.85% to -$23.9 million in 2024, then retreated by 28.22% to -$30.6 million in 2025, then jumped by 155.43% to $17.0 million in 2026.
• Per Business Quant, the three latest TRVI Cash from Investing Activities figures stand at $17.0 million (Q1 2026), -$30.6 million (Q4 2025), and -$50.9 million (Q3 2025).